CIRC (01763) announced that its subsidiary, Atomic High-Tech Co., Ltd., participated in the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," which recently won the first prize in this year's Beijing Medical Science and Technology Award.
Neuroblastoma, the most common extracranial solid tumor in children, accounts for approximately 8%-10% of pediatric malignancies but contributes to 10%-15% of cancer-related deaths in children. Over half of diagnosed cases are classified as high-risk, with a poor prognosis and a five-year survival rate below 50%. Due to its high incidence, recurrence, and mortality rates, neuroblastoma is termed the "king of childhood cancers" and poses a significant public health challenge in China.
The project targeted neuroblastoma as a critical breakthrough, aligning with national strategies for combating major pediatric and rare diseases. Leveraging multimodal nuclear medicine molecular imaging technology, the decade-long research successfully established an innovative chain—from key equipment and core drugs to clinical applications—culminating in a precision diagnosis and treatment system with Chinese characteristics: "multimodal, low-dose, short-duration." This breakthrough offers a Chinese solution to this global medical challenge.
Led by Beijing Friendship Hospital, Atomic High-Tech spearheaded the development of radiopharmaceuticals for neuroblastoma. Key achievements include: - The successful development and market approval of sodium fluoride [18F] injection, a positron radiopharmaceutical for bone imaging, filling a domestic gap. - Leading the formulation of a group standard for sodium iodide [123I] solution, supporting standardized domestic radiopharmaceutical production. - Completing R&D and Phase III trials for gallium [68Ga] DOTATATE injection, advancing neuroblastoma positron radiopharmaceuticals. - Overcoming technical barriers in metaiodobenzylguanidine [123I] injection preparation.
Atomic High-Tech and Beijing Friendship Hospital’s nuclear medicine department have fostered a long-term strategic partnership under the "industry-academia-research-medicine collaborative innovation" model. Their joint efforts in radiopharmaceutical supply, shared research platforms, and clinical trials—including breakthroughs in [123I] MIBG and [18F]/[68Ga] drug trials—laid a solid foundation for the project’s success.
Moving forward, Atomic High-Tech will deepen its commitment to nuclear medicine, prioritizing R&D and innovation in radiopharmaceuticals for major diseases. By strengthening clinical collaborations, the company aims to enhance precision medicine with superior products and services, further safeguarding public health.